CEO: ‘2024 was an excellent year’

Novonesis delivered a strong annual result with an organic sales growth of 8% and an adjusted EBITDA margin of 36.1% in 2024.

Novonesis was founded in January 2024 through the merger of the two Danish companies Novozymes and Chr. Hansen. On Wednesday, the 26th, the company presented the results for its first full financial year. CEO Ester Baiget described it as a strong annual result and called 2024 an excellent year.

In 2024, Novonesis generated revenue of more than €3.9 billion, equivalent to approximately DKK 29.4 billion, an improvement of €1.5 billion compared to the previous year.

The profit for 2024 ended at €276.6 million, equivalent to DKK 2.063 billion.

Sales growth was driven by both Food & Health Biosolutions and Planetary Health Biosolutions. Volume increased by approximately 6%, while pricing contributed around 2% in 2024.

To illustrate Novonesis’ strong focus on innovation, it was highlighted that the company launched 45 new innovations during the year and that around 30% of its 2024 sales came from products introduced within the past five years.

The two divisions, Food & Health and Planetary Health, are expected to continue growing in 2025. Organic growth of 5-8% is projected for 2025, with an adjusted EBITDA margin of 37-38%.

The time for biosolutions is now, and we are determined to seize the unlimited opportunities ahead. Our strategic focus will be on prioritization, innovation, growth, and strengthening our leadership in the biosolutions industry – all with the goal of creating sustainable value for both shareholders and society as a whole,” said CEO Ester Baiget in a statement.